Global Head Lice Drug Market

Head Lice Drug Comprehensive Study by Type (OTC Medication (Permethrin, Pyrethrin, Other), Prescription Medication (Ivermectin, Spinosad, Malathion, Other)), Application (Children, Adult), Form (Lotion, Creams, Shampoo, Other), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) Players and Region - Global Market Outlook to 2030

Head Lice Drug Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Head Lice Drug
Head lice are small, wingless, blood-sucking insects that attack the hair. They feed on the blood of your scalp, which causes irritation or sometimes large pimples on the head. The male lice are much larger compared to the female lice. Head lice are transmissible if you get infected with head lice. Head lice are characterized by symptoms such as severe itching, tingling sensation when the hair moves, and sores on the scalp, neck, and shoulders. Head lice infestation is caused by poor personal hygiene. Head lice can be treated with over-the-counter drugs and prescribed drugs. There are many treatment options available to get rid of head lice, but most treatments need to be used twice or more. The second treatment takes place after a week to kill any newly hatched nits.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)


The companies are now exploring the market by adopting mergers & acquisitions, expansions, investments, new developments in existing products, and collaborations as their preferred strategies. The players are also exploring new geographies and industries through expansions and acquisitions so as to avail a competitive advantage through combined synergies. Analyst at AMA Research estimates that European Players will contribute the maximum growth to Global Head Lice Drug market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Bayer AG (Germany), Alliance Pharmaceuticals Ltd. (United Kingdom), Omega Pharma (Belgium), Arbor Pharmaceuticals Inc. (United States), Prestige Consumer Healthcare Inc. (United States), GlaxoSmithKline (United Kingdom), Merck & Co. (United States), ParaPRO Pharmaceuticals (United States), Fleming Medical Ltd. (Ireland), Perrigo Company plc (Ireland), Stada Arzneimittel (Germany), Reckitt Benckiser Group plc (United Kingdom), Cerecor Inc. (United States) and Medexus Pharmaceuticals (Canada) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Nuvo Pharmaceuticals (Canada), Piedmont Pharmaceuticals LLC (United States) and ICB Pharma (Poland).

Segmentation Overview
AMA Research has segmented the market of Global Head Lice Drug market by Type (OTC Medication [Permethrin, Pyrethrin, Other] and Prescription Medication [Ivermectin, Spinosad, Malathion, Other]), Application (Children and Adult) and Region.



On the basis of geography, the market of Head Lice Drug has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Form, the sub-segment i.e. Lotion will boost the Head Lice Drug market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Distribution Channel, the sub-segment i.e. Hospital Pharmacy will boost the Head Lice Drug market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
New Launches and Emerging New Markets and The High Prevalence and High Disposable Income

Market Growth Drivers:
The Increasing Prevalence and Growing Population of Children Who Are More Prone To Lice Infestation, Lack of Awareness Regarding Personal Hygiene and Easy Availability of Lice Treatment Products

Challenges:
Greater Efficiency in Treatment of Head Lice Requires Constant Combing Regimes, Which Lead To Discomfort in Patients

Restraints:
Lack of Patience in Human Patients

Opportunities:
Increasing Healthcare Expenditure and The Rising Penetration of Market Players

Market Leaders and their expansionary development strategies
In June 2023 – Bayer and Cedilla Therapeutics, a biotechnology company bringing a new dimension to precision oncology, agreement to develop and commercialize Cedilla Therapeutics’ CyclinE1/CDK2 complex inhibitors which selectively address oncogenic drivers.Overexpression or genetic activation of Cyclin Dependent Kinase 2 (CDK2) binding partner cyclin E is a key oncogenic process in several cancers. Cedilla’s small molecules conditionally modulate the protein complex in its functional state resulting in highly selective inhibition. This specific method of action that Cedilla has discovered allows for precise targeting in a selected patient population with high unmet need and has the potential to enhance safety and efficacy in comparison to standard of care.
In February 2020, the U.S. Food and Drug Administration approved a lotion to treat head lice for nonprescription, or over-the-counter (OTC), use through a process called a prescription (Rx)-to-OTC switch.


Key Target Audience
Manufacturers of Head Lice Drug, Suppliers and Distributors of Head Lice Drug, Potential Investors, Market Research Firms, Regulatory Bodies, End-Users and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • OTC Medication [Permethrin, Pyrethrin, Other]
  • Prescription Medication [Ivermectin, Spinosad, Malathion, Other]
By Application
  • Children
  • Adult
By Form
  • Lotion
  • Creams
  • Shampoo
  • Other

By Distribution Channel
  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. The Increasing Prevalence and Growing Population of Children Who Are More Prone To Lice Infestation
      • 3.2.2. Lack of Awareness Regarding Personal Hygiene
      • 3.2.3. Easy Availability of Lice Treatment Products
    • 3.3. Market Challenges
      • 3.3.1. Greater Efficiency in Treatment of Head Lice Requires Constant Combing Regimes, Which Lead To Discomfort in Patients
    • 3.4. Market Trends
      • 3.4.1. New Launches and Emerging New Markets
      • 3.4.2. The High Prevalence and High Disposable Income
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Head Lice Drug, by Type, Application, Form, Distribution Channel and Region (value and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Head Lice Drug (Value)
      • 5.2.1. Global Head Lice Drug by: Type (Value)
        • 5.2.1.1. OTC Medication [Permethrin, Pyrethrin, Other]
        • 5.2.1.2. Prescription Medication [Ivermectin, Spinosad, Malathion, Other]
      • 5.2.2. Global Head Lice Drug by: Application (Value)
        • 5.2.2.1. Children
        • 5.2.2.2. Adult
      • 5.2.3. Global Head Lice Drug by: Form (Value)
        • 5.2.3.1. Lotion
        • 5.2.3.2. Creams
        • 5.2.3.3. Shampoo
        • 5.2.3.4. Other
      • 5.2.4. Global Head Lice Drug by: Distribution Channel (Value)
        • 5.2.4.1. Hospital Pharmacy
        • 5.2.4.2. Online Pharmacy
        • 5.2.4.3. Retail Pharmacy
      • 5.2.5. Global Head Lice Drug Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Head Lice Drug (Price)
      • 5.3.1. Global Head Lice Drug by: Type (Price)
  • 6. Head Lice Drug: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Bayer AG (Germany)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Alliance Pharmaceuticals Ltd. (United Kingdom)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Omega Pharma (Belgium)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Arbor Pharmaceuticals Inc. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Prestige Consumer Healthcare Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. GlaxoSmithKline (United Kingdom)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Merck & Co. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. ParaPRO Pharmaceuticals (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Fleming Medical Ltd. (Ireland)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Perrigo Company plc (Ireland)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Stada Arzneimittel (Germany)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. Reckitt Benckiser Group plc (United Kingdom)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
      • 6.4.13. Cerecor Inc. (United States)
        • 6.4.13.1. Business Overview
        • 6.4.13.2. Products/Services Offerings
        • 6.4.13.3. Financial Analysis
        • 6.4.13.4. SWOT Analysis
      • 6.4.14. Medexus Pharmaceuticals (Canada)
        • 6.4.14.1. Business Overview
        • 6.4.14.2. Products/Services Offerings
        • 6.4.14.3. Financial Analysis
        • 6.4.14.4. SWOT Analysis
  • 7. Global Head Lice Drug Sale, by Type, Application, Form, Distribution Channel and Region (value and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Head Lice Drug (Value)
      • 7.2.1. Global Head Lice Drug by: Type (Value)
        • 7.2.1.1. OTC Medication [Permethrin, Pyrethrin, Other]
        • 7.2.1.2. Prescription Medication [Ivermectin, Spinosad, Malathion, Other]
      • 7.2.2. Global Head Lice Drug by: Application (Value)
        • 7.2.2.1. Children
        • 7.2.2.2. Adult
      • 7.2.3. Global Head Lice Drug by: Form (Value)
        • 7.2.3.1. Lotion
        • 7.2.3.2. Creams
        • 7.2.3.3. Shampoo
        • 7.2.3.4. Other
      • 7.2.4. Global Head Lice Drug by: Distribution Channel (Value)
        • 7.2.4.1. Hospital Pharmacy
        • 7.2.4.2. Online Pharmacy
        • 7.2.4.3. Retail Pharmacy
      • 7.2.5. Global Head Lice Drug Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Head Lice Drug (Price)
      • 7.3.1. Global Head Lice Drug by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Head Lice Drug: by Type(USD Million)
  • Table 2. Head Lice Drug OTC Medication [Permethrin, Pyrethrin, Other] , by Region USD Million (2018-2023)
  • Table 3. Head Lice Drug Prescription Medication [Ivermectin, Spinosad, Malathion, Other] , by Region USD Million (2018-2023)
  • Table 4. Head Lice Drug: by Application(USD Million)
  • Table 5. Head Lice Drug Children , by Region USD Million (2018-2023)
  • Table 6. Head Lice Drug Adult , by Region USD Million (2018-2023)
  • Table 7. Head Lice Drug: by Form(USD Million)
  • Table 8. Head Lice Drug Lotion , by Region USD Million (2018-2023)
  • Table 9. Head Lice Drug Creams , by Region USD Million (2018-2023)
  • Table 10. Head Lice Drug Shampoo , by Region USD Million (2018-2023)
  • Table 11. Head Lice Drug Other , by Region USD Million (2018-2023)
  • Table 12. Head Lice Drug: by Distribution Channel(USD Million)
  • Table 13. Head Lice Drug Hospital Pharmacy , by Region USD Million (2018-2023)
  • Table 14. Head Lice Drug Online Pharmacy , by Region USD Million (2018-2023)
  • Table 15. Head Lice Drug Retail Pharmacy , by Region USD Million (2018-2023)
  • Table 16. South America Head Lice Drug, by Country USD Million (2018-2023)
  • Table 17. South America Head Lice Drug, by Type USD Million (2018-2023)
  • Table 18. South America Head Lice Drug, by Application USD Million (2018-2023)
  • Table 19. South America Head Lice Drug, by Form USD Million (2018-2023)
  • Table 20. South America Head Lice Drug, by Distribution Channel USD Million (2018-2023)
  • Table 21. Brazil Head Lice Drug, by Type USD Million (2018-2023)
  • Table 22. Brazil Head Lice Drug, by Application USD Million (2018-2023)
  • Table 23. Brazil Head Lice Drug, by Form USD Million (2018-2023)
  • Table 24. Brazil Head Lice Drug, by Distribution Channel USD Million (2018-2023)
  • Table 25. Argentina Head Lice Drug, by Type USD Million (2018-2023)
  • Table 26. Argentina Head Lice Drug, by Application USD Million (2018-2023)
  • Table 27. Argentina Head Lice Drug, by Form USD Million (2018-2023)
  • Table 28. Argentina Head Lice Drug, by Distribution Channel USD Million (2018-2023)
  • Table 29. Rest of South America Head Lice Drug, by Type USD Million (2018-2023)
  • Table 30. Rest of South America Head Lice Drug, by Application USD Million (2018-2023)
  • Table 31. Rest of South America Head Lice Drug, by Form USD Million (2018-2023)
  • Table 32. Rest of South America Head Lice Drug, by Distribution Channel USD Million (2018-2023)
  • Table 33. Asia Pacific Head Lice Drug, by Country USD Million (2018-2023)
  • Table 34. Asia Pacific Head Lice Drug, by Type USD Million (2018-2023)
  • Table 35. Asia Pacific Head Lice Drug, by Application USD Million (2018-2023)
  • Table 36. Asia Pacific Head Lice Drug, by Form USD Million (2018-2023)
  • Table 37. Asia Pacific Head Lice Drug, by Distribution Channel USD Million (2018-2023)
  • Table 38. China Head Lice Drug, by Type USD Million (2018-2023)
  • Table 39. China Head Lice Drug, by Application USD Million (2018-2023)
  • Table 40. China Head Lice Drug, by Form USD Million (2018-2023)
  • Table 41. China Head Lice Drug, by Distribution Channel USD Million (2018-2023)
  • Table 42. Japan Head Lice Drug, by Type USD Million (2018-2023)
  • Table 43. Japan Head Lice Drug, by Application USD Million (2018-2023)
  • Table 44. Japan Head Lice Drug, by Form USD Million (2018-2023)
  • Table 45. Japan Head Lice Drug, by Distribution Channel USD Million (2018-2023)
  • Table 46. India Head Lice Drug, by Type USD Million (2018-2023)
  • Table 47. India Head Lice Drug, by Application USD Million (2018-2023)
  • Table 48. India Head Lice Drug, by Form USD Million (2018-2023)
  • Table 49. India Head Lice Drug, by Distribution Channel USD Million (2018-2023)
  • Table 50. South Korea Head Lice Drug, by Type USD Million (2018-2023)
  • Table 51. South Korea Head Lice Drug, by Application USD Million (2018-2023)
  • Table 52. South Korea Head Lice Drug, by Form USD Million (2018-2023)
  • Table 53. South Korea Head Lice Drug, by Distribution Channel USD Million (2018-2023)
  • Table 54. Taiwan Head Lice Drug, by Type USD Million (2018-2023)
  • Table 55. Taiwan Head Lice Drug, by Application USD Million (2018-2023)
  • Table 56. Taiwan Head Lice Drug, by Form USD Million (2018-2023)
  • Table 57. Taiwan Head Lice Drug, by Distribution Channel USD Million (2018-2023)
  • Table 58. Australia Head Lice Drug, by Type USD Million (2018-2023)
  • Table 59. Australia Head Lice Drug, by Application USD Million (2018-2023)
  • Table 60. Australia Head Lice Drug, by Form USD Million (2018-2023)
  • Table 61. Australia Head Lice Drug, by Distribution Channel USD Million (2018-2023)
  • Table 62. Rest of Asia-Pacific Head Lice Drug, by Type USD Million (2018-2023)
  • Table 63. Rest of Asia-Pacific Head Lice Drug, by Application USD Million (2018-2023)
  • Table 64. Rest of Asia-Pacific Head Lice Drug, by Form USD Million (2018-2023)
  • Table 65. Rest of Asia-Pacific Head Lice Drug, by Distribution Channel USD Million (2018-2023)
  • Table 66. Europe Head Lice Drug, by Country USD Million (2018-2023)
  • Table 67. Europe Head Lice Drug, by Type USD Million (2018-2023)
  • Table 68. Europe Head Lice Drug, by Application USD Million (2018-2023)
  • Table 69. Europe Head Lice Drug, by Form USD Million (2018-2023)
  • Table 70. Europe Head Lice Drug, by Distribution Channel USD Million (2018-2023)
  • Table 71. Germany Head Lice Drug, by Type USD Million (2018-2023)
  • Table 72. Germany Head Lice Drug, by Application USD Million (2018-2023)
  • Table 73. Germany Head Lice Drug, by Form USD Million (2018-2023)
  • Table 74. Germany Head Lice Drug, by Distribution Channel USD Million (2018-2023)
  • Table 75. France Head Lice Drug, by Type USD Million (2018-2023)
  • Table 76. France Head Lice Drug, by Application USD Million (2018-2023)
  • Table 77. France Head Lice Drug, by Form USD Million (2018-2023)
  • Table 78. France Head Lice Drug, by Distribution Channel USD Million (2018-2023)
  • Table 79. Italy Head Lice Drug, by Type USD Million (2018-2023)
  • Table 80. Italy Head Lice Drug, by Application USD Million (2018-2023)
  • Table 81. Italy Head Lice Drug, by Form USD Million (2018-2023)
  • Table 82. Italy Head Lice Drug, by Distribution Channel USD Million (2018-2023)
  • Table 83. United Kingdom Head Lice Drug, by Type USD Million (2018-2023)
  • Table 84. United Kingdom Head Lice Drug, by Application USD Million (2018-2023)
  • Table 85. United Kingdom Head Lice Drug, by Form USD Million (2018-2023)
  • Table 86. United Kingdom Head Lice Drug, by Distribution Channel USD Million (2018-2023)
  • Table 87. Netherlands Head Lice Drug, by Type USD Million (2018-2023)
  • Table 88. Netherlands Head Lice Drug, by Application USD Million (2018-2023)
  • Table 89. Netherlands Head Lice Drug, by Form USD Million (2018-2023)
  • Table 90. Netherlands Head Lice Drug, by Distribution Channel USD Million (2018-2023)
  • Table 91. Rest of Europe Head Lice Drug, by Type USD Million (2018-2023)
  • Table 92. Rest of Europe Head Lice Drug, by Application USD Million (2018-2023)
  • Table 93. Rest of Europe Head Lice Drug, by Form USD Million (2018-2023)
  • Table 94. Rest of Europe Head Lice Drug, by Distribution Channel USD Million (2018-2023)
  • Table 95. MEA Head Lice Drug, by Country USD Million (2018-2023)
  • Table 96. MEA Head Lice Drug, by Type USD Million (2018-2023)
  • Table 97. MEA Head Lice Drug, by Application USD Million (2018-2023)
  • Table 98. MEA Head Lice Drug, by Form USD Million (2018-2023)
  • Table 99. MEA Head Lice Drug, by Distribution Channel USD Million (2018-2023)
  • Table 100. Middle East Head Lice Drug, by Type USD Million (2018-2023)
  • Table 101. Middle East Head Lice Drug, by Application USD Million (2018-2023)
  • Table 102. Middle East Head Lice Drug, by Form USD Million (2018-2023)
  • Table 103. Middle East Head Lice Drug, by Distribution Channel USD Million (2018-2023)
  • Table 104. Africa Head Lice Drug, by Type USD Million (2018-2023)
  • Table 105. Africa Head Lice Drug, by Application USD Million (2018-2023)
  • Table 106. Africa Head Lice Drug, by Form USD Million (2018-2023)
  • Table 107. Africa Head Lice Drug, by Distribution Channel USD Million (2018-2023)
  • Table 108. North America Head Lice Drug, by Country USD Million (2018-2023)
  • Table 109. North America Head Lice Drug, by Type USD Million (2018-2023)
  • Table 110. North America Head Lice Drug, by Application USD Million (2018-2023)
  • Table 111. North America Head Lice Drug, by Form USD Million (2018-2023)
  • Table 112. North America Head Lice Drug, by Distribution Channel USD Million (2018-2023)
  • Table 113. United States Head Lice Drug, by Type USD Million (2018-2023)
  • Table 114. United States Head Lice Drug, by Application USD Million (2018-2023)
  • Table 115. United States Head Lice Drug, by Form USD Million (2018-2023)
  • Table 116. United States Head Lice Drug, by Distribution Channel USD Million (2018-2023)
  • Table 117. Canada Head Lice Drug, by Type USD Million (2018-2023)
  • Table 118. Canada Head Lice Drug, by Application USD Million (2018-2023)
  • Table 119. Canada Head Lice Drug, by Form USD Million (2018-2023)
  • Table 120. Canada Head Lice Drug, by Distribution Channel USD Million (2018-2023)
  • Table 121. Mexico Head Lice Drug, by Type USD Million (2018-2023)
  • Table 122. Mexico Head Lice Drug, by Application USD Million (2018-2023)
  • Table 123. Mexico Head Lice Drug, by Form USD Million (2018-2023)
  • Table 124. Mexico Head Lice Drug, by Distribution Channel USD Million (2018-2023)
  • Table 125. Head Lice Drug: by Type(USD/Units)
  • Table 126. Company Basic Information, Sales Area and Its Competitors
  • Table 127. Company Basic Information, Sales Area and Its Competitors
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Company Basic Information, Sales Area and Its Competitors
  • Table 140. Head Lice Drug: by Type(USD Million)
  • Table 141. Head Lice Drug OTC Medication [Permethrin, Pyrethrin, Other] , by Region USD Million (2025-2030)
  • Table 142. Head Lice Drug Prescription Medication [Ivermectin, Spinosad, Malathion, Other] , by Region USD Million (2025-2030)
  • Table 143. Head Lice Drug: by Application(USD Million)
  • Table 144. Head Lice Drug Children , by Region USD Million (2025-2030)
  • Table 145. Head Lice Drug Adult , by Region USD Million (2025-2030)
  • Table 146. Head Lice Drug: by Form(USD Million)
  • Table 147. Head Lice Drug Lotion , by Region USD Million (2025-2030)
  • Table 148. Head Lice Drug Creams , by Region USD Million (2025-2030)
  • Table 149. Head Lice Drug Shampoo , by Region USD Million (2025-2030)
  • Table 150. Head Lice Drug Other , by Region USD Million (2025-2030)
  • Table 151. Head Lice Drug: by Distribution Channel(USD Million)
  • Table 152. Head Lice Drug Hospital Pharmacy , by Region USD Million (2025-2030)
  • Table 153. Head Lice Drug Online Pharmacy , by Region USD Million (2025-2030)
  • Table 154. Head Lice Drug Retail Pharmacy , by Region USD Million (2025-2030)
  • Table 155. South America Head Lice Drug, by Country USD Million (2025-2030)
  • Table 156. South America Head Lice Drug, by Type USD Million (2025-2030)
  • Table 157. South America Head Lice Drug, by Application USD Million (2025-2030)
  • Table 158. South America Head Lice Drug, by Form USD Million (2025-2030)
  • Table 159. South America Head Lice Drug, by Distribution Channel USD Million (2025-2030)
  • Table 160. Brazil Head Lice Drug, by Type USD Million (2025-2030)
  • Table 161. Brazil Head Lice Drug, by Application USD Million (2025-2030)
  • Table 162. Brazil Head Lice Drug, by Form USD Million (2025-2030)
  • Table 163. Brazil Head Lice Drug, by Distribution Channel USD Million (2025-2030)
  • Table 164. Argentina Head Lice Drug, by Type USD Million (2025-2030)
  • Table 165. Argentina Head Lice Drug, by Application USD Million (2025-2030)
  • Table 166. Argentina Head Lice Drug, by Form USD Million (2025-2030)
  • Table 167. Argentina Head Lice Drug, by Distribution Channel USD Million (2025-2030)
  • Table 168. Rest of South America Head Lice Drug, by Type USD Million (2025-2030)
  • Table 169. Rest of South America Head Lice Drug, by Application USD Million (2025-2030)
  • Table 170. Rest of South America Head Lice Drug, by Form USD Million (2025-2030)
  • Table 171. Rest of South America Head Lice Drug, by Distribution Channel USD Million (2025-2030)
  • Table 172. Asia Pacific Head Lice Drug, by Country USD Million (2025-2030)
  • Table 173. Asia Pacific Head Lice Drug, by Type USD Million (2025-2030)
  • Table 174. Asia Pacific Head Lice Drug, by Application USD Million (2025-2030)
  • Table 175. Asia Pacific Head Lice Drug, by Form USD Million (2025-2030)
  • Table 176. Asia Pacific Head Lice Drug, by Distribution Channel USD Million (2025-2030)
  • Table 177. China Head Lice Drug, by Type USD Million (2025-2030)
  • Table 178. China Head Lice Drug, by Application USD Million (2025-2030)
  • Table 179. China Head Lice Drug, by Form USD Million (2025-2030)
  • Table 180. China Head Lice Drug, by Distribution Channel USD Million (2025-2030)
  • Table 181. Japan Head Lice Drug, by Type USD Million (2025-2030)
  • Table 182. Japan Head Lice Drug, by Application USD Million (2025-2030)
  • Table 183. Japan Head Lice Drug, by Form USD Million (2025-2030)
  • Table 184. Japan Head Lice Drug, by Distribution Channel USD Million (2025-2030)
  • Table 185. India Head Lice Drug, by Type USD Million (2025-2030)
  • Table 186. India Head Lice Drug, by Application USD Million (2025-2030)
  • Table 187. India Head Lice Drug, by Form USD Million (2025-2030)
  • Table 188. India Head Lice Drug, by Distribution Channel USD Million (2025-2030)
  • Table 189. South Korea Head Lice Drug, by Type USD Million (2025-2030)
  • Table 190. South Korea Head Lice Drug, by Application USD Million (2025-2030)
  • Table 191. South Korea Head Lice Drug, by Form USD Million (2025-2030)
  • Table 192. South Korea Head Lice Drug, by Distribution Channel USD Million (2025-2030)
  • Table 193. Taiwan Head Lice Drug, by Type USD Million (2025-2030)
  • Table 194. Taiwan Head Lice Drug, by Application USD Million (2025-2030)
  • Table 195. Taiwan Head Lice Drug, by Form USD Million (2025-2030)
  • Table 196. Taiwan Head Lice Drug, by Distribution Channel USD Million (2025-2030)
  • Table 197. Australia Head Lice Drug, by Type USD Million (2025-2030)
  • Table 198. Australia Head Lice Drug, by Application USD Million (2025-2030)
  • Table 199. Australia Head Lice Drug, by Form USD Million (2025-2030)
  • Table 200. Australia Head Lice Drug, by Distribution Channel USD Million (2025-2030)
  • Table 201. Rest of Asia-Pacific Head Lice Drug, by Type USD Million (2025-2030)
  • Table 202. Rest of Asia-Pacific Head Lice Drug, by Application USD Million (2025-2030)
  • Table 203. Rest of Asia-Pacific Head Lice Drug, by Form USD Million (2025-2030)
  • Table 204. Rest of Asia-Pacific Head Lice Drug, by Distribution Channel USD Million (2025-2030)
  • Table 205. Europe Head Lice Drug, by Country USD Million (2025-2030)
  • Table 206. Europe Head Lice Drug, by Type USD Million (2025-2030)
  • Table 207. Europe Head Lice Drug, by Application USD Million (2025-2030)
  • Table 208. Europe Head Lice Drug, by Form USD Million (2025-2030)
  • Table 209. Europe Head Lice Drug, by Distribution Channel USD Million (2025-2030)
  • Table 210. Germany Head Lice Drug, by Type USD Million (2025-2030)
  • Table 211. Germany Head Lice Drug, by Application USD Million (2025-2030)
  • Table 212. Germany Head Lice Drug, by Form USD Million (2025-2030)
  • Table 213. Germany Head Lice Drug, by Distribution Channel USD Million (2025-2030)
  • Table 214. France Head Lice Drug, by Type USD Million (2025-2030)
  • Table 215. France Head Lice Drug, by Application USD Million (2025-2030)
  • Table 216. France Head Lice Drug, by Form USD Million (2025-2030)
  • Table 217. France Head Lice Drug, by Distribution Channel USD Million (2025-2030)
  • Table 218. Italy Head Lice Drug, by Type USD Million (2025-2030)
  • Table 219. Italy Head Lice Drug, by Application USD Million (2025-2030)
  • Table 220. Italy Head Lice Drug, by Form USD Million (2025-2030)
  • Table 221. Italy Head Lice Drug, by Distribution Channel USD Million (2025-2030)
  • Table 222. United Kingdom Head Lice Drug, by Type USD Million (2025-2030)
  • Table 223. United Kingdom Head Lice Drug, by Application USD Million (2025-2030)
  • Table 224. United Kingdom Head Lice Drug, by Form USD Million (2025-2030)
  • Table 225. United Kingdom Head Lice Drug, by Distribution Channel USD Million (2025-2030)
  • Table 226. Netherlands Head Lice Drug, by Type USD Million (2025-2030)
  • Table 227. Netherlands Head Lice Drug, by Application USD Million (2025-2030)
  • Table 228. Netherlands Head Lice Drug, by Form USD Million (2025-2030)
  • Table 229. Netherlands Head Lice Drug, by Distribution Channel USD Million (2025-2030)
  • Table 230. Rest of Europe Head Lice Drug, by Type USD Million (2025-2030)
  • Table 231. Rest of Europe Head Lice Drug, by Application USD Million (2025-2030)
  • Table 232. Rest of Europe Head Lice Drug, by Form USD Million (2025-2030)
  • Table 233. Rest of Europe Head Lice Drug, by Distribution Channel USD Million (2025-2030)
  • Table 234. MEA Head Lice Drug, by Country USD Million (2025-2030)
  • Table 235. MEA Head Lice Drug, by Type USD Million (2025-2030)
  • Table 236. MEA Head Lice Drug, by Application USD Million (2025-2030)
  • Table 237. MEA Head Lice Drug, by Form USD Million (2025-2030)
  • Table 238. MEA Head Lice Drug, by Distribution Channel USD Million (2025-2030)
  • Table 239. Middle East Head Lice Drug, by Type USD Million (2025-2030)
  • Table 240. Middle East Head Lice Drug, by Application USD Million (2025-2030)
  • Table 241. Middle East Head Lice Drug, by Form USD Million (2025-2030)
  • Table 242. Middle East Head Lice Drug, by Distribution Channel USD Million (2025-2030)
  • Table 243. Africa Head Lice Drug, by Type USD Million (2025-2030)
  • Table 244. Africa Head Lice Drug, by Application USD Million (2025-2030)
  • Table 245. Africa Head Lice Drug, by Form USD Million (2025-2030)
  • Table 246. Africa Head Lice Drug, by Distribution Channel USD Million (2025-2030)
  • Table 247. North America Head Lice Drug, by Country USD Million (2025-2030)
  • Table 248. North America Head Lice Drug, by Type USD Million (2025-2030)
  • Table 249. North America Head Lice Drug, by Application USD Million (2025-2030)
  • Table 250. North America Head Lice Drug, by Form USD Million (2025-2030)
  • Table 251. North America Head Lice Drug, by Distribution Channel USD Million (2025-2030)
  • Table 252. United States Head Lice Drug, by Type USD Million (2025-2030)
  • Table 253. United States Head Lice Drug, by Application USD Million (2025-2030)
  • Table 254. United States Head Lice Drug, by Form USD Million (2025-2030)
  • Table 255. United States Head Lice Drug, by Distribution Channel USD Million (2025-2030)
  • Table 256. Canada Head Lice Drug, by Type USD Million (2025-2030)
  • Table 257. Canada Head Lice Drug, by Application USD Million (2025-2030)
  • Table 258. Canada Head Lice Drug, by Form USD Million (2025-2030)
  • Table 259. Canada Head Lice Drug, by Distribution Channel USD Million (2025-2030)
  • Table 260. Mexico Head Lice Drug, by Type USD Million (2025-2030)
  • Table 261. Mexico Head Lice Drug, by Application USD Million (2025-2030)
  • Table 262. Mexico Head Lice Drug, by Form USD Million (2025-2030)
  • Table 263. Mexico Head Lice Drug, by Distribution Channel USD Million (2025-2030)
  • Table 264. Head Lice Drug: by Type(USD/Units)
  • Table 265. Research Programs/Design for This Report
  • Table 266. Key Data Information from Secondary Sources
  • Table 267. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Head Lice Drug: by Type USD Million (2018-2023)
  • Figure 5. Global Head Lice Drug: by Application USD Million (2018-2023)
  • Figure 6. Global Head Lice Drug: by Form USD Million (2018-2023)
  • Figure 7. Global Head Lice Drug: by Distribution Channel USD Million (2018-2023)
  • Figure 8. South America Head Lice Drug Share (%), by Country
  • Figure 9. Asia Pacific Head Lice Drug Share (%), by Country
  • Figure 10. Europe Head Lice Drug Share (%), by Country
  • Figure 11. MEA Head Lice Drug Share (%), by Country
  • Figure 12. North America Head Lice Drug Share (%), by Country
  • Figure 13. Global Head Lice Drug: by Type USD/Units (2018-2023)
  • Figure 14. Global Head Lice Drug share by Players 2023 (%)
  • Figure 15. Global Head Lice Drug share by Players (Top 3) 2023(%)
  • Figure 16. Global Head Lice Drug share by Players (Top 5) 2023(%)
  • Figure 17. BCG Matrix for key Companies
  • Figure 18. Bayer AG (Germany) Revenue, Net Income and Gross profit
  • Figure 19. Bayer AG (Germany) Revenue: by Geography 2023
  • Figure 20. Alliance Pharmaceuticals Ltd. (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 21. Alliance Pharmaceuticals Ltd. (United Kingdom) Revenue: by Geography 2023
  • Figure 22. Omega Pharma (Belgium) Revenue, Net Income and Gross profit
  • Figure 23. Omega Pharma (Belgium) Revenue: by Geography 2023
  • Figure 24. Arbor Pharmaceuticals Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 25. Arbor Pharmaceuticals Inc. (United States) Revenue: by Geography 2023
  • Figure 26. Prestige Consumer Healthcare Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 27. Prestige Consumer Healthcare Inc. (United States) Revenue: by Geography 2023
  • Figure 28. GlaxoSmithKline (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 29. GlaxoSmithKline (United Kingdom) Revenue: by Geography 2023
  • Figure 30. Merck & Co. (United States) Revenue, Net Income and Gross profit
  • Figure 31. Merck & Co. (United States) Revenue: by Geography 2023
  • Figure 32. ParaPRO Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 33. ParaPRO Pharmaceuticals (United States) Revenue: by Geography 2023
  • Figure 34. Fleming Medical Ltd. (Ireland) Revenue, Net Income and Gross profit
  • Figure 35. Fleming Medical Ltd. (Ireland) Revenue: by Geography 2023
  • Figure 36. Perrigo Company plc (Ireland) Revenue, Net Income and Gross profit
  • Figure 37. Perrigo Company plc (Ireland) Revenue: by Geography 2023
  • Figure 38. Stada Arzneimittel (Germany) Revenue, Net Income and Gross profit
  • Figure 39. Stada Arzneimittel (Germany) Revenue: by Geography 2023
  • Figure 40. Reckitt Benckiser Group plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 41. Reckitt Benckiser Group plc (United Kingdom) Revenue: by Geography 2023
  • Figure 42. Cerecor Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 43. Cerecor Inc. (United States) Revenue: by Geography 2023
  • Figure 44. Medexus Pharmaceuticals (Canada) Revenue, Net Income and Gross profit
  • Figure 45. Medexus Pharmaceuticals (Canada) Revenue: by Geography 2023
  • Figure 46. Global Head Lice Drug: by Type USD Million (2025-2030)
  • Figure 47. Global Head Lice Drug: by Application USD Million (2025-2030)
  • Figure 48. Global Head Lice Drug: by Form USD Million (2025-2030)
  • Figure 49. Global Head Lice Drug: by Distribution Channel USD Million (2025-2030)
  • Figure 50. South America Head Lice Drug Share (%), by Country
  • Figure 51. Asia Pacific Head Lice Drug Share (%), by Country
  • Figure 52. Europe Head Lice Drug Share (%), by Country
  • Figure 53. MEA Head Lice Drug Share (%), by Country
  • Figure 54. North America Head Lice Drug Share (%), by Country
  • Figure 55. Global Head Lice Drug: by Type USD/Units (2025-2030)
List of companies from research coverage that are profiled in the study
  • Bayer AG (Germany)
  • Alliance Pharmaceuticals Ltd. (United Kingdom)
  • Omega Pharma (Belgium)
  • Arbor Pharmaceuticals Inc. (United States)
  • Prestige Consumer Healthcare Inc. (United States)
  • GlaxoSmithKline (United Kingdom)
  • Merck & Co. (United States)
  • ParaPRO Pharmaceuticals (United States)
  • Fleming Medical Ltd. (Ireland)
  • Perrigo Company plc (Ireland)
  • Stada Arzneimittel (Germany)
  • Reckitt Benckiser Group plc (United Kingdom)
  • Cerecor Inc. (United States)
  • Medexus Pharmaceuticals (Canada)
Additional players considered in the study are as follows:
Nuvo Pharmaceuticals (Canada) , Piedmont Pharmaceuticals LLC (United States) , ICB Pharma (Poland)
Select User Access Type

Key Highlights of Report


Mar 2024 201 Pages 76 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Head Lice Drug Market Quantitative research analysis
Global Head Lice Drug Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Bayer AG (Germany), Alliance Pharmaceuticals Ltd. (United Kingdom), Omega Pharma (Belgium), Arbor Pharmaceuticals Inc. (United States), Prestige Consumer Healthcare Inc. (United States), GlaxoSmithKline (United Kingdom), Merck & Co. (United States), ParaPRO Pharmaceuticals (United States), Fleming Medical Ltd. (Ireland), Perrigo Company plc (Ireland), Stada Arzneimittel (Germany), Reckitt Benckiser Group plc (United Kingdom), Cerecor Inc. (United States) and Medexus Pharmaceuticals (Canada) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"New Launches and Emerging New Markets " is seen as one of major influencing trends for Head Lice Drug Market during projected period 2023-2030.
The Head Lice Drug market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Head Lice Drug Market Report?

Have a Query? Click Here

Other Related Reports

Swallowing Disorder Products Comprehensive Study by Type (Food Products, Powder Thickener, Ready-to-drink thickened beverages, Oral nutritional supplements, Feeding Aids & Tubes), Sales Distribution ...
$ 3450
Panacis Quinquefolis Comprehensive Study by Application (Anxiety, Mental Disorder, Menopause, Type 2 Diabetes, Heart Disease, Cancer, Alzheimer), Form (Fragment, Capsule, Powder, Others), Parts Used ...
$ 3500
Ossotide Tablets Comprehensive Study by Application (Fractures, Osteoarthritis, Rheumatism, Rheumatoid Arthritis), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online) Players and Re...
$ 3500
Bacampicillin Comprehensive Study by Application (Pneumonia, Bronchitis, Tract Infections, Skin Infections, Others), Patient Type (Adult, Pediatric), Distribution Channel (Hospital Pharmacy, Online P...
$ 3450
Neutropenia Drugs Comprehensive Study by Type (Congenital Neutropenia, Idiopathic, Cyclic Neutropenia, Autoimmune Neutropenia), By Drug type (Capsule, Injection), End User (Hospital, Clinics) Players...
$ 3500
Multimodal Imaging Comprehensive Study by Type (Systems, Software, Reagents), Application (Neuropsychiatry, Cardiology, Oncology, Ophthalmology, Others), Technology (PET-CT Systems, SPECT-CT Systems,...
$ 3450